Aveo Pharmaceuticals (AVEO) 1.23 $AVEO
AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:18AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Can the Uptrend Continue for AVEO Pharmaceuticals (AVEO)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 8:42AM CDT
Can the Uptrend Continue for AVEO Pharmaceuticals (AVEO)?
Conference Call Schedules, Acquisitions, and Public Offerings - Analyst Notes on Johnson & Johnson, Merck, GW, Endocyte and AVEO
PR Newswire - Fri Jun 20, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), GW Pharmaceuticals plc (NASDAQ: GWPH), Endocyte, Inc. (NASDAQ: ECYT) and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3944-100free.
AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:46AM CDT
AVEO Pharmaceuticals (AVEO) was a big mover last session, with shares rising over 11% on the day.
AVEO Pharmaceuticals, Inc. (AVEO) in Focus: Stock Rises 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 7:44AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Pharmacovigilance Conference 2014 - 17th-18th June 2014, London UK
M2 - Thu Jun 05, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnzqmj/3rd) has announced the addition of the "3rd Pharmacovigilance Conference 2014" conference to their offering. Ramada Encore London West, UK - 17th-18th June 2014 Key Speakers: - Dr Gyorgy Zorenyl, Senior Global Safety Physician, Astrazeneca - Dr Bert van Leeuwen, Deputy (QPVV) of Pharmacovigilance, Astellas - Dr Ester Pena van Leeuwen, Medical Advisor in Pharmacovigilance, Boehringer - Ingelheim - Dr Anil Dhiri, Consultant Business Analyst, Oracle - Dr Kevin Woodward, Senior Consultant, TSGE - Ms Humaira Qureshi, VP Pharmacovigilance Outsourcing, Kinapse - Dr Pipasha Biswas, Director & QPPV, Symogen - Dr Dimitrios M Antoniadis, Director Pharmacoviglance, Pharmathen S.A - Dr Dennis Vargo, Head of Pharmacovigilance, AVEO Pharmaceuticals - Dr Shelley Gandhi, Director of Pharmacovigilance, NDA Regulatory Science Ltd - Dr Steve Hutson, Co-founder, Virtual PV Limited - Dr Nawab Qizilbash, Head, OXON Epidemiology Key Topics Covered: Day 1: 09:00 Registration and refreshments 09:30 Opening address from the chair 09:40 Current challenges facing the pharmacovigilance industry - Achieving QbD objectives - QbD and continuous improvement in manufacturing - Design space and control strategy - The use of MVDA models to ensure quality compliance in routine production 10:20 Implementing the New EU Good Pharmacoviliance Practice Modules - The new EU GVP Modules - Patient Safety & Public Health - Impact of Modules on Pharmacovigilance Departments 11:00 Morning refreshments 11:20 Pharmacovigilance: Contribution Towards Corporate Development - Pharmacovigilance metrics/ KPI's - Pharmacovigilance Contribution towards patient safety - Pharmacoviliance as a business model 12:00 Data Integration for Safety - Need for & types of data integration - Trials versus epidemiological studies - ENCePP discussions at the EMA 12:40 Networking lunch 13.40 Effective risk management: strategies to leverage patient safety - Safety specification - New aspects of the pharmacovigilance plan - Effective risk minimization and risk communication 14:20 Integrating Clinical Safety & Spontaneous Reporting - Challenges for System integration - Optimism business processes - Regulatory Challenges 15:00 Afternoon refreshments 15:20 Mobile Apps in Pharma Development - Current Status of Healthcare/ Pharma /Apps - Potential Apps in Pharmaceutical R & D - Developing Implementing and benefits of Apps 16:00 Environmental aspects of Human and Veterinary pharmaceuticals - Adverse environmental effects part of veterinary pharmacovigilance - Human and veterinary drugs ubiquitous in environment - Human health effects unknown 16:40 Closing remarks from the chair 16:50 Networking drinks Day 2: 09:00 Registration and refreshments 09:30 Opening address from the chair 09:40 Hepatotoxicity Assesment - Hepatotoxicity - DILI - Assessing DILI causality 10:20 Quality Assurance within PV - The requirements of PV legislation - QA system set up - Metrics and KPIs 11:00 Morning refreshments 11:20 Filing a MAA in Europe does PV legislation affect you? - Key elements in EU MAA process: Day 80, 120 - RMPs, PASS, Additional Monitoring - PV System Summary, PSMF & QMS - A pre-authorization Audit what does this mean? 12:00 Experience with REMS/RMP development when these territories are covered by separate co-development partners - Pharmacovigilance - Risk Management - REMs 12:40 Networking lunch 13:40 Quality of Data, new business rules to create a more solid base for data mining and statistics - New techniques in data mining and statistics - Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs - Governance and the management process 14:20 Drug Safety on a Budget - Drug Safety and Risk Management - Examine the costs of running PV and RM - Examine the monetary aspects of out-sourcing 15:00 Afternoon refreshments 15:20 The future of pharmacovigilance within industry Our expert panel will discuss and debate on the future and progression of pharmacovigilance opportunities and operational challenges to working environments 16:40 Chair's closing remarks 16:50 End of conference For more information visit http://www.researchandmarkets.com/research/lnzqmj/3rd
AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting
Business Wire - Sat May 31, 1:20PM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO's ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. The results were presented in a poster, entitled "First-in-human Phase 1 dose-escalation study of AV-203, a monoclonal antibody against ErbB3 in patients with metastatic or advanced solid tumors" (Abstract #11113, Poster #395, S Hall A2), at the Tumor Biology General Poster Session of the American Society of Clinical Oncology 2014 Annual Meeting, taking place May 30 - June 3, 2014, in Chicago.
AVEO Oncology to Present at the Jefferies Global Healthcare Conference
Business Wire - Wed May 28, 5:30AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City.
PTC Therapeutics Up on Positive CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 2:22PM CDT
The CHMP provided a positive opinion on the marketing authorization of PTC Therapeutics' (PTCT) Translarna.
Sarepta to Acquire Manufacturing Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 3:45PM CDT
Sarepta (SRPT) to acquire a multifunctional manufacturing facility in Massachusetts for $25 million.
Technical Pointers on Top Gainers -- Research on Newfield Exploration, Endocyte, Columbia Property Trust, and AVEO Pharma
PR Newswire - Mon Mar 24, 9:09AM CDT
The US markets saw mixed sentiments on Friday, March 21, 2014, with the NASDAQ Composite closing at 4,276.79, down 0.98%, the Dow Jones Industrial Average ending the session at 16,302.77, down 0.17% and the S&P 500 edging 0.29% lower to finish the trading session at 1,866.52. During the session, gains in the Energy, Utilities, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Discretionary, Information Technology, and Health Care sectors. A number of stocks saw large movements, including Newfield Exploration Co. (NYSE: NFX), Endocyte Inc. (NASDAQ: ECYT), Columbia Property Trust Inc. (NYSE: CXP) and AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). Free technical research on NFX, ECYT, CXP and AVEO can be downloaded upon signing up at:
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
AVEO Oncology regains worldwide rights to AV-203 and seeks partner to accelerate its clinical development
M2 - Fri Mar 21, 5:42AM CDT
Biopharmaceutical company AVEO Oncology (NasdaqGS:AVEO) said on Thursday that it has re -acquired the worldwide rights to AV-203 from Biogen Idec.
AVEO Regains Worldwide Rights to AV-203
Business Wire - Thu Mar 20, 3:30PM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.
AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
Business Wire - Thu Mar 13, 2:22PM CDT
--- Focuses internal R&D investment on AV-380 in cachexia -
AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:18AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Can the Uptrend Continue for AVEO Pharmaceuticals (AVEO)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 8:42AM CDT
Can the Uptrend Continue for AVEO Pharmaceuticals (AVEO)?
Conference Call Schedules, Acquisitions, and Public Offerings - Analyst Notes on Johnson & Johnson, Merck, GW, Endocyte and AVEO
PR Newswire - Fri Jun 20, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), GW Pharmaceuticals plc (NASDAQ: GWPH), Endocyte, Inc. (NASDAQ: ECYT) and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3944-100free.
AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:46AM CDT
AVEO Pharmaceuticals (AVEO) was a big mover last session, with shares rising over 11% on the day.
AVEO Pharmaceuticals, Inc. (AVEO) in Focus: Stock Rises 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 7:44AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Pharmacovigilance Conference 2014 - 17th-18th June 2014, London UK
M2 - Thu Jun 05, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnzqmj/3rd) has announced the addition of the "3rd Pharmacovigilance Conference 2014" conference to their offering. Ramada Encore London West, UK - 17th-18th June 2014 Key Speakers: - Dr Gyorgy Zorenyl, Senior Global Safety Physician, Astrazeneca - Dr Bert van Leeuwen, Deputy (QPVV) of Pharmacovigilance, Astellas - Dr Ester Pena van Leeuwen, Medical Advisor in Pharmacovigilance, Boehringer - Ingelheim - Dr Anil Dhiri, Consultant Business Analyst, Oracle - Dr Kevin Woodward, Senior Consultant, TSGE - Ms Humaira Qureshi, VP Pharmacovigilance Outsourcing, Kinapse - Dr Pipasha Biswas, Director & QPPV, Symogen - Dr Dimitrios M Antoniadis, Director Pharmacoviglance, Pharmathen S.A - Dr Dennis Vargo, Head of Pharmacovigilance, AVEO Pharmaceuticals - Dr Shelley Gandhi, Director of Pharmacovigilance, NDA Regulatory Science Ltd - Dr Steve Hutson, Co-founder, Virtual PV Limited - Dr Nawab Qizilbash, Head, OXON Epidemiology Key Topics Covered: Day 1: 09:00 Registration and refreshments 09:30 Opening address from the chair 09:40 Current challenges facing the pharmacovigilance industry - Achieving QbD objectives - QbD and continuous improvement in manufacturing - Design space and control strategy - The use of MVDA models to ensure quality compliance in routine production 10:20 Implementing the New EU Good Pharmacoviliance Practice Modules - The new EU GVP Modules - Patient Safety & Public Health - Impact of Modules on Pharmacovigilance Departments 11:00 Morning refreshments 11:20 Pharmacovigilance: Contribution Towards Corporate Development - Pharmacovigilance metrics/ KPI's - Pharmacovigilance Contribution towards patient safety - Pharmacoviliance as a business model 12:00 Data Integration for Safety - Need for & types of data integration - Trials versus epidemiological studies - ENCePP discussions at the EMA 12:40 Networking lunch 13.40 Effective risk management: strategies to leverage patient safety - Safety specification - New aspects of the pharmacovigilance plan - Effective risk minimization and risk communication 14:20 Integrating Clinical Safety & Spontaneous Reporting - Challenges for System integration - Optimism business processes - Regulatory Challenges 15:00 Afternoon refreshments 15:20 Mobile Apps in Pharma Development - Current Status of Healthcare/ Pharma /Apps - Potential Apps in Pharmaceutical R & D - Developing Implementing and benefits of Apps 16:00 Environmental aspects of Human and Veterinary pharmaceuticals - Adverse environmental effects part of veterinary pharmacovigilance - Human and veterinary drugs ubiquitous in environment - Human health effects unknown 16:40 Closing remarks from the chair 16:50 Networking drinks Day 2: 09:00 Registration and refreshments 09:30 Opening address from the chair 09:40 Hepatotoxicity Assesment - Hepatotoxicity - DILI - Assessing DILI causality 10:20 Quality Assurance within PV - The requirements of PV legislation - QA system set up - Metrics and KPIs 11:00 Morning refreshments 11:20 Filing a MAA in Europe does PV legislation affect you? - Key elements in EU MAA process: Day 80, 120 - RMPs, PASS, Additional Monitoring - PV System Summary, PSMF & QMS - A pre-authorization Audit what does this mean? 12:00 Experience with REMS/RMP development when these territories are covered by separate co-development partners - Pharmacovigilance - Risk Management - REMs 12:40 Networking lunch 13:40 Quality of Data, new business rules to create a more solid base for data mining and statistics - New techniques in data mining and statistics - Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs - Governance and the management process 14:20 Drug Safety on a Budget - Drug Safety and Risk Management - Examine the costs of running PV and RM - Examine the monetary aspects of out-sourcing 15:00 Afternoon refreshments 15:20 The future of pharmacovigilance within industry Our expert panel will discuss and debate on the future and progression of pharmacovigilance opportunities and operational challenges to working environments 16:40 Chair's closing remarks 16:50 End of conference For more information visit http://www.researchandmarkets.com/research/lnzqmj/3rd
AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting
Business Wire - Sat May 31, 1:20PM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO's ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. The results were presented in a poster, entitled "First-in-human Phase 1 dose-escalation study of AV-203, a monoclonal antibody against ErbB3 in patients with metastatic or advanced solid tumors" (Abstract #11113, Poster #395, S Hall A2), at the Tumor Biology General Poster Session of the American Society of Clinical Oncology 2014 Annual Meeting, taking place May 30 - June 3, 2014, in Chicago.
AVEO Oncology to Present at the Jefferies Global Healthcare Conference
Business Wire - Wed May 28, 5:30AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City.
PTC Therapeutics Up on Positive CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 2:22PM CDT
The CHMP provided a positive opinion on the marketing authorization of PTC Therapeutics' (PTCT) Translarna.
Sarepta to Acquire Manufacturing Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 3:45PM CDT
Sarepta (SRPT) to acquire a multifunctional manufacturing facility in Massachusetts for $25 million.
Technical Pointers on Top Gainers -- Research on Newfield Exploration, Endocyte, Columbia Property Trust, and AVEO Pharma
PR Newswire - Mon Mar 24, 9:09AM CDT
The US markets saw mixed sentiments on Friday, March 21, 2014, with the NASDAQ Composite closing at 4,276.79, down 0.98%, the Dow Jones Industrial Average ending the session at 16,302.77, down 0.17% and the S&P 500 edging 0.29% lower to finish the trading session at 1,866.52. During the session, gains in the Energy, Utilities, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Discretionary, Information Technology, and Health Care sectors. A number of stocks saw large movements, including Newfield Exploration Co. (NYSE: NFX), Endocyte Inc. (NASDAQ: ECYT), Columbia Property Trust Inc. (NYSE: CXP) and AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). Free technical research on NFX, ECYT, CXP and AVEO can be downloaded upon signing up at:
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
AVEO Oncology regains worldwide rights to AV-203 and seeks partner to accelerate its clinical development
M2 - Fri Mar 21, 5:42AM CDT
Biopharmaceutical company AVEO Oncology (NasdaqGS:AVEO) said on Thursday that it has re -acquired the worldwide rights to AV-203 from Biogen Idec.
AVEO Regains Worldwide Rights to AV-203
Business Wire - Thu Mar 20, 3:30PM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.
AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
Business Wire - Thu Mar 13, 2:22PM CDT
--- Focuses internal R&D investment on AV-380 in cachexia -
AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
